Identification of key molecular targets for stachyose in hepatocellular carcinoma: focus on STAT3 and FN1

Haihua Chen1, Xianyou Wang2, Jiongcheng Ying3

  • 1Department of Hepatobiliary Surgery, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.

Frontiers in Oncology
|August 7, 2025
PubMed
Abstract

Insights

Stachyose (STA) may treat hepatocellular carcinoma (HCC) by targeting STAT3 and FN1. This study identified these key genes and validated STA's anti-cancer effects in vitro, offering potential therapeutic applications for HCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • Hepatocellular carcinoma (HCC) is a prevalent global malignancy.
  • Stachyose (STA), an oligosaccharide from legumes, exhibits anti-tumor properties.
  • STA demonstrates potential in improving gut microbiota and reducing oxidative stress.

Purpose of the Study:

  • To predict potential molecular targets of Stachyose (STA) in Hepatocellular Carcinoma (HCC) treatment.
  • To identify key hub genes involved in STA's therapeutic mechanism against HCC.
  • To validate the therapeutic potential of STA in HCC through molecular and experimental approaches.

Main Methods:

  • Integrated public databases and bioinformatics tools to screen STA targets in HCC.
  • Constructed Stachyose action and protein-protein interaction (PPI) networks.
  • Performed functional enrichment analysis, molecular docking, and in vitro experimental validation.

Main Results:

  • Identified 34 common targets for STA and HCC, with STAT3 and FN1 selected as core hub genes.
  • STAT3 and FN1 are implicated in angiogenesis, tumor inflammation, and epithelial-mesenchymal transition (EMT).
  • In vitro experiments confirmed STA inhibits HCC proliferation and migration by downregulating STAT3 and FN1.

Conclusions:

  • This study elucidates the molecular mechanisms of STA in HCC treatment.
  • STAT3 and FN1 are identified as key therapeutic targets for STA in HCC.
  • STA shows clinical relevance and potential for HCC therapeutic applications.